News and Reports
-
Arcutis Announces Positive Topline Data from Phase 2 Clinical Trial Evaluating ARQ-154 (Topical Ro
29 September 2020Download -
Sanofi Completes Principia Biopharma Inc. Acquisition
28 September 2020Download -
BioShin, Biohaven's Asia-Pacific Subsidiary, Raises $60M in Series A Funding to Advance Neuroscience Pipeline in Asia-Pacific Region
28 September 2020Download -
Monte Rosa Therapeutics Announces $96 Million Series B Financing to Advance Small Molecule-based Protein Degradation Platform
24 September 2020Download -
Novellus Closes $57M Series C Financing
21 September 2020Download -
Polyneuron Extends Series A to CHF 36.5 Million with Additional CHF 14 Million
16 September 2020Download -
Seer Announces Spin Out of PrognomIQ with $55 Million Initial Financing
15 September 2020Download -
NiKang Therapeutics Completes $50 Million Series B Financing
14 September 2020Download -
Arcutis Biotherapeutics to Accelerate ARQ-151 (Topical Roflumilast Cream) into Phase 3 Trials for the Treatment of Atopic Dermatitis Following End-of-Phase 2 Meeting with FDA
8 September 2020Download -
Andrew Hirsch Named Chief Executive Officer of C4 Therapeutics
8 September 2020Download -
Connect Biopharma Completes $115 Million Series C Financing to Advance Ongoing Clinical Trials in Atopic Dermatitis and Ulcerative Colitis and Initiate Additional Clinical Programs
24 August 2020Download -
Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio
24 August 2020Download -
iTeos Therapeutics Announces Pricing of Initial Public Offering
23 July 2020Download -
SpringWorks Therapeutics Announces Full Enrollment of Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Desmoid Tumors
22 July 2020Download -
Bioatla Raises $72.5 Million in Series D Financing
15 July 2020Download -
C4 Therapeutics Raises $170 Million Financing to Bring Robust Pipeline of Protein Degraders to Clinical Proof-of-concept and to Advance Proprietary Platform
16 June 2020Download -
Viela Bio Announces U.S. FDA Approval of UPLIZNA? (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
11 June 2020Download -
Novo Nordisk to acquire Corvidia Therapeutics and expand presence in cardiovascular disease
11 June 2020Download -
Everest Medicines Completes US$310 Million Series C Financing
4 June 2020Download -
Swixx and Amryt sign CEE Distriubtion Deal on Myalepta June 3, 2020
3 June 2020Download -
Y-mAbs Announces U.S. FDA Acceptance of Biologics License Application for Danyelza? (Naxitamab) for the Treatment of Neuroblastoma for Priority Review
2 June 2020Download -
Galecto Appoints New Chair and Strengthens Board of Directors
19 May 2020Download -
iTeos Therapeutics Presents Data from First-in-Human Study of A2A Receptor Antagonist at AACR Virtual Annual Meeting 2020
27 April 2020Download -
Y-mAbs enters into Worldwide Exclusive License Agreement for SADA Technology – a Novel Radioimmunotherapy Platform
15 April 2020Download -
iTeos Therapeutics Closes $125 Million Series B2 Financing
1 April 2020Download